Why Is MyMD Pharmaceuticals Stock Gaining Today?

MyMD Pharmaceuticals Inc MYMD announced topline results from its randomized Phase 2 study of oral TNF-α inhibitor, MYMD-1, in patients with chronic inflammation associated with sarcopenia or age-related frailty

The study met its primary endpoint of significantly reducing chronic inflammatory markers in participants treated with MYMD-1. 

MYMD-1 has the potential to be the first drug approved by the FDA for sarcopenia, an age-related decline in physical function.

The study met both of its primary endpoints, significantly reducing serum levels of three biomarkers, TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03), and maintaining appropriate plasma concentrations and parameters in pharmacokinetic evaluations. 

The study also achieved all secondary endpoints related to safety and tolerability. 

There were no treatment-related adverse events (AEs) or serious adverse events (SAEs) over the course of the study.

The Phase 2 multi-center double-blind, placebo-controlled, randomized study was designed to investigate the efficacy, tolerability, and pharmacokinetics of MYMD-1 in participants aged 65 years or older with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines. 

Patients in the study were dosed weekly with MYMD-1 or placebo over 28 days. The study consisted of four dosing cohorts versus placebo (600mg, 750mg, 900mg, and 1050mg).

Full results from the study will be presented or published at a later date to be determined. The company plans to initiate discussions with the FDA regarding a Phase 3 study of MYMD-1 in sarcopenia.

Price Action: MYMD shares are up 5.45% at $1.16 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!